AVEO Share Price

Open 3.01 Change Price %
High 3.05 1 Day -0.04 -1.33
Low 2.89 1 Week 0.00 0.00
Close 2.97 1 Month -0.63 -17.50
Volume 1480481 1 Year 2.34 371.43
52 Week High 4.24
52 Week Low 0.54
AVEO Important Levels
Resistance 2 3.12
Resistance 1 3.06
Pivot 2.97
Support 1 2.88
Support 2 2.82
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)

AVEO Technical Analysis 2
As on 31st Oct 2017 AVEO Share Price closed @ 2.97 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.62 & Strong Sell for SHORT-TERM with Stoploss of 3.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
AVEO Target for May
1st Target up-side 3.81
2nd Target up-side 4.41
3rd Target up-side 5
1st Target down-side 2.13
2nd Target down-side 1.53
3rd Target down-side 0.94
AVEO Other Details
Segment EQ
Market Capital 320564000.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.aveopharma.com
AVEO Address
650 East Kendall Street
Cambridge, MA 02142
United States
Phone: 617-299-5000
AVEO Latest News
Interactive Technical Analysis Chart AVEO Pharmaceuticals, Inc. ( AVEO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AVEO Pharmaceuticals, Inc.
AVEO Business Profile
AVEO Pharmaceuticals, Inc., incorporated on October 19, 2001, is a cancer therapeutics company discovering, developing and commercializing targeted cancer therapies. The Company’s Human Response Platform, a method of building preclinical models of human cancer, provides the Company with insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. Tivozanib is the Company’s lead product candidate, which the Company partnered with Astellas Pharma Inc. (Astellas) during the year ended December 31, 2011. Tivozanib is an inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. In January 2012, the Company announced data from its global, phase III clinical trial of tivozanib, a therapy for first-line treatment in renal cell carcinoma (RCC), which the Company refers to as the TIVO-1 study. The TIVO-1 study is being conducted in patients with advanced clear cell RCC, who have undergone a prior nephrectomy (kidney removal) and who have not received any prior VEGF- and mTOR-targeted therapy. In this trial, the Company measured, among other things, each patient’s progression-free survival (PFS), which refers to the period of time that began when a patient entered the clinical trial and ended when either the patient died or the patient’s cancer had grown by a specified percentage or spread to a new location in the body. PFS is the primary endpoint in the TIVO-1 study. In the TIVO-1 study, tivozanib demonstrated a statistically significant improvement in PFS with a median PFS of 11.9 months for tivozanib. Tivozanib also demonstrated a statistically significant improvement in PFS with a median PFS of 12.7 months in the pre-specified subpopulation of patients who received no prior systemic anti-cancer therapy for metastatic disease-a subpopulation that comprised approximately 70% of the total study population. In the TIVO-1 study, tivozanib demonstrated a well-tolerated safety profile consistent with the results from its tivozanib phase II clinical trial in patients with advanced RCC; the commonly reported side effect was hypertension. The common treatment-related side effects seen in the phase II clinical trial were hypertension (44.9%) and dysphonia, or hoarseness of voice (21.7%). Additionally, the incidence of other side effects in the phase II clinical trial that are commonly associated with other VEGF receptor inhibitors, such as diarrhea, rash, mucositis, stomatitis, fatigue, and hand-foot syndrome, was relatively low.